Can we know what to do when DCIS is diagnosed?

Oncology

Volumn 25, Issue 9, 2011, Pages

  Sanders, Melinda E ^a   Simpson, Jean F ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; BREAST NECROSIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONSERVATIVE TREATMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE BIOPSY; PARTIAL MASTECTOMY; POSTOPERATIVE CARE; TUMOR BIOPSY;

EID: 80053636198     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Dupont W, Page D. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-51.
2. London S, Connolly J, Schnitt S, Colditz G. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992;267:941-4.
3. Dupont W, Parl F, Hartmann W, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71:1258-65.
4. Hartmann L, Sellers T, Frost M, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229-37.
5. Sanders M, Schuyler P, Dupont W, Page D. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103:2481-4.
6. Collins L, Tamimi R, Baer H, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005;103:1778-84.
7. Betsill W, Jr, Rosen P, Lieberman P, Robbins G. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA. 1978;239:1863-7.
8. Saul S. Prone to error: earliest steps to find cancer. The New York Times. July 20, 2010.
9. Simpson J, Sanders M, Page D, editors. Diagnostic accuracy of ductal carcinoma in situ: results of Eastern Cooperative Oncology Trial 5194. USCAP; March 2011; San Antonio, TX.
10. Page DL, Dupont WD, Rogers LW, et al. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995;76:1197-1200.
11. Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005;103:1778-84.
12. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340:1455-61.
13. Guerra LE, Smith RM, Kaminski A, et al. Invasive local recurrence increased after radiation therapy for ductal carcinoma in situ. Am J Surg. 2008;196:552-5.
14. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006;24:1031-6.
15. Silverstein MJ, Lagios MD. Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? No. One size does not fit all: an argument against the routine use of radiation therapy for all patients with ductal carcinoma in situ of the breast who elect breast conservation. J Surg Oncol. 2007;95:605-9.
16. Ozanne EM, Shieh Y, Barnes J, et al. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat. 2011;129:165-73.
17. Grin A, Horne G, Ennis M, O'Malley FP. Measuring extent of ductal carcinoma in situ in breast excision specimens: a comaprison of four methods. Arch Pathol Lab Med. 2009;133:31-7.
18. Dadmanesh F, Fan X, Dastane A, et al. Comparative analysis of size estimation by mapping and counting number of blocks with ductal carcinoma in situ in breast excision specimens. Arch Pathol Lab Med. 2009;133:26-30.
19. O'Sullivan M, Li T, Freedman G, Morrow M. The effect of multiple reexcisions on the risk of local recurrence after breast conserving surgery. Ann Surg Oncol. 2007;14:3133-40.
20. Silverstein M Lagios M, Recht A, et al. Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg. 2005;201:586-97.
21. Cheng L, Al-Kaisi NK, Gordon NH, et al. Relationship between the size and margin status of ductal carcinoma in situ of the breast and residual disease. J Natl Cancer Inst. 1997;89:1356-60.
22. Di Saverio S, Catena F, Santini D, et al. 259 patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat. 2008;109:405-16.
23. MacDonald HR, Silverstein MJ, Mabry H, et al. Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am J Surg. 2005;190:521-5.
24. Sigal-Zafrani B, Lewis JS, Clough KB, et al. Histological margin assessment for breast ductal carcinoma in situ: precision and implications. Mod Pathol. 2004;17:81-8.
25. Dillon MF, Mc Dermott EW, O'Doherty A, et al. Factors affecting successful breast conservation for ductal carcinoma in situ. Ann Surg Oncol. 2007;14:1618-28.
26. Neuschatz A, DiPetrillo T, Steinhoff M, et al. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. Cancer. 2002;94:1917-24.
27. Asjoe FT, Altintas S, Huizing MT, et al. The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis. Breast J. 2007;13:359-67.
28. Muffuz A, Barroso-Bravo S, Najera I, et al. Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ. J Exp Clin Cancer Res. 2006;25:223-7.
29. Lester SC, Bose S, Chen YY, et al. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009;133:1515-38.
30. Patchefsky AS, Schwartz GF, Finkelstein SD, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer. 1989;63:731-41.
31. Bellamy CO, McDonald C, Salter DM, et al. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol. 1993;24:16-23.
32. Boland GP, Chan KC, Knox WF, et al. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg. 2003;90:426-32.
33. Neuschatz AC, Di Petrillo T, Steinhoff M, et al. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. Cancer. 2002;94:1917-24.
34. Macdonald HR, Silverstein MJ, Lee LA, et al. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast. Am J Surg. 2006;192:420-2.
35. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400-18.
36. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381-7.
37. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial. Lancet. 2003;362:95-102.
38. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999;86:429-38.
39. Bijker N, Peerse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001;19:2263-71.
40. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087-2106.
41. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:5319-24.
42. Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg. 2003;186:337-43.
43. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355:528-33.
44. Moore KH, Sweeney KJ, Wilson ME, et al. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit. Ann Surg Oncol. 2007;14:2911-7.
45. Mabry H, Giuliano AE, Silverstein MJ. What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ? Am J Surg. 2006;192:455-7.
46. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2011;2:232-61.
47. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312.